BIO vs SYRE
Bio-Rad Laboratories vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
BIO
Bio-Rad Laboratories
59
Buy
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | BIO | SYRE |
|---|
| AI Score |
59
|
67
|
| Price |
$379.85
|
$106.50
|
| P/E Ratio |
45.62×
|
-54.61×
|
| ROE |
10.2%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.9%
|
0.0%
|
| Debt / Equity |
0.17×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
82.3
|
57.1
|
| Beta |
1.047
|
3.026
|
| Expected Upside |
+0.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for BIO versus SYRE.
SYRE leads by 8 points.
SYRE scores 67/100 (Buy) versus BIO at 59/100 (Buy).
BIO Committee View
67% agreement
6 analysts
Positive signals support the current rating — news sentiment is positive (+0.57 across 7 articles, 14d). The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 43.5 is expensive by classic value standards — Value
- ROE of only 3.1% -- cheap may mean cheap for a reason — Value
- EPS declining -29.6% YoY despite any revenue growth — Growth
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical